Report Categories
View AllRecent Articles
View All
Saratoga SAZ Q1 2026 Results Fall Short EPS 016 Revenue NA
GEE Group JOB Q4 2025 Earnings Miss Sparks Concern
Lucky LUCK Q1 2026 Results Fall Short EPS 010 Revenue NA
GameStops eBay Bid Faces Hurdle InvestmentGrade Credit Requirement in Ryan Cohens Bank Letter
Apollo Commercial Real Estate Finance ARI Hovers Near Support Amid Modest Decline
Grindr GRND Slides 183 Fear or Fundamentals 20260521
PPL Corporation Corporate Units PPLC Gains 16 Approaches Key Resistance Level
Musk Slams Altman Trial Verdict as a Technicality Vows to Appeal in HighProfile AI Dispute
Alan Milburn Criticizes UK Welfare Spending on Youth as Shameful Amid Calls for Reform
US Dollar Holds Near SixWeek High as Iran Tensions Boost SafeHaven Demand
ONGC Reports 46 Surge in Q4 Net Profit Revenue Up 4
Smallcase Managers Predict Nifty 50 Could Reach 2800030000 by FY27 Amid Earnings Optimism
Analyst Report Highlights Resilience of HF Sinclair Corp Amid Refining Market Dynamics
Micron Reaches 1 Trillion Market Cap on AIDriven Memory Demand Surge
CURV Q1 2026 Earnings EPS Surprise Signals Operational Improvement
ClearOne CLRO Q2 2018 Earnings EPS Surpasses Estimates as Stock Climbs 545
CLDI Q4 2025 Earnings Smallerthanexpected loss highlights progress in clinicalstage biotherapeutics
Evolv Technologies Q1 2026 Earnings Narrowing Loss Beats Expectations Stock Rises
CGTX Q1 2026 Earnings Cognition Therapeutics Reports NarrowerThanExpected Loss No Revenue Yet
External Links
Guzman y Gomez Exits US Market Citing Intense Competition and High Costs
Amcor plc AMCR Q1 2026 Earnings EPS Misses Estimates Amid Cost Headwinds
RDZN Roadzen Inc Ordinary Shares reports sharp Q1 2026 EPS miss as quarterly revenue declines 52 percent year over year
Trinity TRINI Growth Potential Q4 2025 Profit Disappoints
ANI Pharma ANIP Stock Investment Potential Insight 365 20260418
Is FTAI FTAIM stock worth watching today Q4 2025 Profit Disappoints
Aptevo APVO Sector Impact Aptevo Therapeutics posts 999 EPS surprise far narrower loss than expected
SLXNW Silexion reports no quarterly revenue as therapeutics pipeline advances CEO signals strategic focus on clinical milestones ahead
Is Universal ULH stock hiding in plain sight Investor Concern 20260507